Clete A. Kushida, M.D., Ph.D.

Clinical Focus

• Neurology
• Sleep Disorders
• Sleep Medicine

Administrative Appointments

• President, World Sleep Federation (2011 - present)
• Medical Director, Stanford Sleep Medicine Center (2010 - present)
• President, American Academy of Sleep Medicine (2009 - 2010)
• Founding/Inaugural President, California Sleep Society (2008 - 2010)
• Board Of Directors, American Academy of Sleep Medicine (2005 - 2011)

Professional Education

Community and International Work

• APPLES - Apnea Positive-Pressure Long-Term Efficacy Study, Stanford Univ; Harvard Univ; Univ of Arizona; St. Luke's Hospital, MO; St. Mary's Hospital, WA 

Internet Links

• Stanford Sleep Medicine Center
• Stanford Center for Sleep Sciences and Medicine
• Center for Human Sleep Research

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information

Current Research Interests

Dr. Kushida is a neurologist and sleep specialist who directs several NIH- and industry-sponsored research studies, focused on topics such as the physical features and neurocognitive changes associated with the obstructive sleep apnea syndrome, the epidemiology and treatment of restless legs syndrome/periodic limb movement disorder, primary care sleep education and training, and countermeasures for sleep loss.

Clinical Trials

• MA 09-09: Pediatric Nasal Mask Usability Study Recruiting
• A Clinical Research Study of MK-6096 for Primary Insomnia No longer recruiting
• AERO C009: Provent Device Study Completed
• Apnea Positive Pressure Long-Term Efficacy Study No longer recruiting
• CEPH 4026: C10953/4026/AP/US - Armodafinil Drug Study Completed

Publications

• A method for estimating normative distributions for study-specific populations of clinical trials. Holmes TH, Nichols DA, Thomander D, Kushida CA. Contemp Clin Trials. 2012; 33 (2): 445-9
• Risk for obstructive sleep apnea in obese, nondiabetic adults varies with insulin resistance status. Liu A, Kushida CA, Reaven GM. Sleep Breath. 2012
• Positive airway pressure initiation: a randomized controlled trial to assess the impact of therapy mode and titration process on efficacy, adherence, and outcomes. Kushida CA, Berry RB, Blau A, Crabtree T, Fietze I, Kryger MH, Kuna ST, Pegram GV, Penzel T. Sleep. 2011; 34 (8): 1083-92
• Reliability and validity of two self-administered questionnaires for screening restless legs syndrome in population-based studies. Popat RA, Van Den Eeden SK, Tanner CM, Kushida CA, Rama AN, Black JE, Bernstein A, Kasten M, Chade A, Leimpeter A, Cassidy J, McGuire V, Nelson LM. Sleep Med. 2010; 11 (2): 154-60
• Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW. Clin Neuropharmacol. 2009 Nov-Dec; 32 (6): 311-20